Editorial orientation provided by MedAPI — not part of the coding instruction.
C12 denotes a primary malignant neoplasm arising in the pyriform sinus (pyriform fossa), a paired subsite of the hypopharynx. Tobacco and alcohol exposure are major risk factors, and tumors often present at an advanced local or nodal stage because early lesions may cause few symptoms.
Common Histologies
- Conventional squamous cell carcinoma, by far the most common histology
- Less commonly, variants of squamous carcinoma or malignancies arising from minor salivary glands and other tissues
Common Symptoms
- Progressive dysphagia or odynophagia (R13.10)
- Persistent sore throat or foreign-body sensation (R09.A2) (R09.A2)
- Referred otalgia (H92.09)
- Neck mass from cervical nodal metastasis (C77.0)
- Hoarseness (R49.0), cough (R05.9), aspiration (J69.0), or airway symptoms (R06.9)
- Unintentional weight loss or malnutrition (R63.4)
- Hemoptysis or blood-streaked saliva in some cases (R04.2)
Diagnosis
Evaluation generally includes complete head and neck examination, flexible nasopharyngolaryngoscopy, and biopsy for histopathologic confirmation. Examination under anesthesia with direct laryngoscopy may help define submucosal or adjacent-site extension.
Contrast-enhanced CT or MRI of the neck assesses local invasion and cervical lymph nodes. Chest imaging and, for more advanced disease, FDG PET/CT may be used to evaluate regional and distant spread and to identify synchronous tobacco-related malignancies. Baseline dental, nutritional, speech, swallowing, and airway assessments are often important before treatment.
Staging
Staging follows the TNM system for hypopharyngeal carcinoma. Tumor category reflects factors such as tumor dimensions, involvement of multiple hypopharyngeal subsites, vocal cord fixation, and invasion of adjacent structures. Regional staging considers cervical nodal burden, laterality, size, and extranodal extension. The lungs are a common site of distant metastasis.
Molecular Markers
HPV-driven biology is less characteristic of pyriform sinus carcinoma than of oropharyngeal carcinoma. Consequently, p16 positivity should not automatically be interpreted as HPV-mediated disease or used to apply HPV-associated oropharyngeal staging. PD-L1 expression may inform systemic treatment selection in recurrent or metastatic squamous cell carcinoma. Broader molecular testing may be considered in advanced disease when it could identify an actionable alteration or clinical-trial option.
Common Treatments
Management depends on stage, resectability, functional considerations, and patient fitness:
- Early-stage disease may be treated with definitive radiation therapy or selected organ-preserving surgery.
- Locally advanced disease commonly requires concurrent chemoradiation or surgery followed by risk-adapted radiation or chemoradiation.
- Surgical treatment may include partial or total laryngopharyngectomy with appropriate neck dissection, depending on extent.
- Recurrent or metastatic disease may be treated with immune checkpoint inhibition, platinum-based systemic therapy, cetuximab-containing regimens, palliative radiation, salvage surgery, or clinical trials.
- Supportive care may include airway management, enteral nutrition, pain control, smoking and alcohol cessation support, dental care, and speech and swallowing rehabilitation.
Scope Note
C12 identifies the primary anatomic site as the pyriform sinus or pyriform fossa. It does not encode histologic subtype, grade, TNM stage, nodal status, distant metastases, HPV or other biomarker status, laterality, treatment status, or tobacco/alcohol exposure. Secondary malignant deposits should not be represented as a primary C12 neoplasm, and tumors centered in another hypopharyngeal site or overlapping adjacent sites should be classified according to the documented primary site.